Skip to main content
TipRanks
Go Ultimate75% OFF

HC Surgical Specialists Ltd (1B1) AI Stock Analysis

5 Followers
SG:1B1

HC Surgical Specialists Ltd

(SGX:1B1)

Select Model
Rating:74.5Outperform
Price Target:SGD 0.38â–²(21.29% Upside)
Action:reiterated
Date:11/03/26

The score is driven primarily by strong financial performance (especially robust, consistent cash generation and a de-risked balance sheet) and attractive valuation (low P/E and high dividend yield). These positives are tempered by weak technicals, with the price below major moving averages and negative MACD signaling a softer trend.

Positive Factors
Robust cash generationConsistently positive operating and free cash flow indicates that reported profits convert into usable cash, supporting reinvestment and shareholder returns. The close relationship between free cash flow and net income also suggests earnings quality is solid, while strong 2026 free cash flow growth adds support to near-term financial resilience.
Negative Factors
Uneven revenue growthThe multi-year pattern of revenue declines followed by a later rebound shows that growth has not been consistently predictable. Uneven top-line performance can make capacity planning and earnings forecasting more difficult, and it raises the importance of sustaining the recent recovery rather than treating the 2026 improvement as an established trend.

HC Surgical Specialists Ltd (1B1) vs. iShares MSCI Singapore ETF (EWS)

-5%0%5%10%15%20%25%30%SG:1B1-3.13%EWS+6.71%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SGD 47.55M
Dividend Yield
6.71%
Average Volume (3M)
17.47K
Price to Earnings (P/E)
7.3
Beta (1Y)
0.28
Revenue Growth
1.42%
EPS Growth
-17.12%
Country
Singapore
Employees
18
Sector
Healthcare
Sector Strength
51
Industry
Medical - Diagnostics & Research

HC Surgical Specialists Ltd Business Overview & Revenue Model

Company Description

HC Surgical Specialists Limited, an investment holding company, primarily delivers a diverse spectrum of medical services across Singapore. Through its network of clinics, the company specializes in endoscopic procedures, such as gastroscopies and co...

HC Surgical Specialists Ltd Financial Statement Overview

Summary

Strong overall fundamentals led by consistently positive operating/free cash flow with high cash conversion, improving balance sheet leverage and solid ROE. Offsetting factors are uneven revenue and earnings trends in 2022–2024 and some margin/earnings volatility, which creates uncertainty about sustainability despite the 2026 rebound.

Income Statement

72Positive

Balance Sheet

82Very Positive

Cash Flow

88Very Positive
Financial statement breakdown
BreakdownTTMMay 2025May 2024May 2023May 2022May 2021
Income Statement
Total Revenue19.22M19.38M19.11M18.81M19.08M19.31M
Gross Profit8.70M6.29M16.11M15.96M16.45M16.67M
EBITDA7.14M6.59M10.88M7.01M5.96M9.59M
Net Income8.73M6.98M8.44M3.85M2.92M6.38M
Balance Sheet
Total Assets28.93M32.56M27.27M27.84M31.26M30.96M
Cash, Cash Equivalents and Short-Term Investments6.96M8.08M5.73M8.06M10.26M6.93M
Total Debt2.40M2.69M2.78M4.34M5.50M6.25M
Total Liabilities6.14M11.98M6.52M13.37M19.18M19.74M
Stockholders Equity23.11M20.91M20.95M14.69M12.10M11.00M
Cash Flow
Free Cash Flow6.85M7.71M6.75M6.23M6.51M6.83M
Operating Cash Flow7.33M7.80M7.23M6.30M7.22M7.05M
Investing Cash Flow1.53M158.00K-444.00K2.84M-1.72M-1.99M
Financing Cash Flow-9.11M-5.28M-9.05M-7.97M-6.24M-9.12M

HC Surgical Specialists Ltd Technical Analysis

Technical Analysis SentimentNegative
Last Price0.31

Price Trends

50DMA0.34Negative
100DMA0.35Negative
200DMA0.35Negative

Market Momentum

MACD-0.01Positive
RSI30.87Neutral
STOCH9.09Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:1B1, the sentiment is Negative. The current price of 0.31 is below the 20-day moving average (MA) of 0.34, below the 50-day MA of 0.34, and below the 200-day MA of 0.35, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 30.87 is Neutral, neither overbought nor oversold. The STOCH value of 9.09 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SG:1B1.

HC Surgical Specialists Ltd Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SG:1B1 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SG:1B1SG:1B175OutperformSGD 47.68M7.3329.03%6.71%1.42%-17.12%
SG:OTXSG:OTX74OutperformSGD 29.60M8.7219.60%11.45%-3.11%-21.50%
SG:8K7SG:8K753NeutralSGD 43.67M20.591.27%―4.69%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-25%0%25%50%75%SG:1B1SG:1J5SG:546SG:8K7SG:MIJSG:OTXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SG:1B1 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SG:1B1HC Surgical Specialists Ltd0.31-0.01-3.13%
SG:1J5Hyphens Pharma International Ltd.0.350.039.37%
SG:546Medtecs International Corporation Ltd.0.09-0.03-21.67%
SG:8K7UG Healthcare Corp. Ltd.0.07-0.03-27.84%
SG:MIJAlliance Healthcare Group Ltd.0.180.0763.64%
SG:OTXMedinex Ltd.0.22-0.00-1.35%

HC Surgical Specialists Ltd Corporate Events

HC Surgical Specialists expands orthopaedic network with new Gleneagles Hospital centre

Oct 16, 2026

HC Surgical Specialists’ associated company Total Orthopaedics Pte. Ltd. has secured a medical licence for its new orthopaedic centre, Total Orthopaedic Care & Surgery (GEH), at Gleneagles Hospital, marking the group’s first orthopaedic clinic within...

HC Surgical Specialists Secures Unanimous Shareholder Backing at 2026 AGM

Oct 16, 2026

HC Surgical Specialists held its annual general meeting in Singapore on 29 September 2026, where shareholders reviewed the FY2026 audited financial statements and received updates on business performance, including non-operating income, dividend yiel...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 03, 2026